Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock

British Journal of Pharmacology

Volumn 127, Issue 2, 1999, Pages 482-488

  Squadrito, Francesco ^a   Altavilla, Domenica ^a   Squadrito, Giovanni ^a   Campo, Giuseppe M ^a   Arlotta, Mariarita ^a   Quartarone, Cristina ^a   Saitta, Antonino ^a   Caputi, Achille P ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Inducible nitric oxide synthase; Recombinant human erythropoietin; Splanchnic artery occlusion shock; Vascular dysfunction

Indexed keywords

ENDOTOXIN; NITRATE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE COUNT; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE ACTIVATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SHOCK; VASCULAR DISEASE; VASCULAR RING;

ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CONSTRICTION, PATHOLOGIC; ENZYME INHIBITORS; ERYTHROCYTE COUNT; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; SHOCK; SPLANCHNIC CIRCULATION; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032987496     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702521     Document Type: Article

References (29)

1. Acquit, C.H.I., Ferragu-Haguet, M., Lefebvre, A., Berthelot, J.M., Peterlongo, F. & Castaingne, J.P. (1987). Recombinant erythropoietin and blood pressure. Lancet, 2, 1083.
2. Buemi, M., Allegra, A., Squadrito, F., Buemi, A.L., Lagana', A., Aloisi, C. & Frisina, N. (1993). Effects of intravenous administration of recombinant human erythropoietin in rats subjected to hemorrhagic shock. Nephron, 65, 440-443.
3. Caputi, A.P., Rossi, F., Carney, K. & Brezenoff, H.E. (1980). Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats. J. Pharmacol. Exp. Ther., 215, 309-316.
4. Casati, S., Passerini, P., Campise, M.R., Graziani, G. & Cesana, B. (1987). Benefits and risk of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br. Med. J., 23, 1017-1020.
5. Ding, A.H., Nathan, C.F. & Stuehr, D.J. (1988). Release of reactive nitrogen intermediates from mouse peritoneal macrophages. J. Immunol., 141, 2407-2412.
6. Edmunds, M.E. & Walls, J. (1988). Blood pressure and erythropoietin. Lancet, 1, 352-353.
7. Egrie, J.C., Strickland, T.W., Lane, J., Aoki, K. & Cohen, A.M. (1986). Characterization and biological effects of recombinant human erythropoietin. Immunobiology, 172, 213-224.
8. Erslev, A.J. (1991). Erythropoietin. New. Engl. J. Med., 324, 1339-1344.
9. Heidenreich, S., Rahn, K.H. & Zidek, W. (1991). Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int., 39, 259-265.
10. Hulse, E.V. (1964). Quantitative cell counts of the bone marrow and blood and their secular variations in the normal adult rats. Acta Haemat., 31, 50-63.
11. Iwamoto, J. & Morin, F.C. (1993). Nitric oxide inhibition varies with hemoglobin saturation. J. Appl. Physiol., 75, 2332-2336.
12. Jacobs, K., Shoemaker, C. & Rudersdorf, R. (1985). Isolation and characterization of genomic and cDNA clones of human erythropoietin. Lancet, 313, 806-810.
13. Jelkmann, W. (1992). Erythropoietin: structure, control of production and function. Physiol. Rev., 72, 449-489.
14. Mayer, G., Cada, E.M., Watzinger, U., Ludvik, G., Barbas, U. & Graf, H. (198). Pathophysiology of hypertension in dialysis patients treated with erythropoietin (abstract). Kidney Int., 35, 319.
15. Moncada, S., Plamer, R.M.J. & Higgs, E.A. (1991). Nitric oxide: physiology, Rimar, S. & Gillis, C.M. (1993). Selective pulmonary vasodilation by inhaled nitric oxide is pathophysiology and pharmacology. Pharmacol. Rev., 43, 109-142.
16. Moncada, S., Plamer, R.M.J. & Higgs, E.A. (1991). Nitric oxide: physiology, Rimar, S. & Gillis, C.M. (1993). Selective pulmonary vasodilation by inhaled nitric oxide is pathophysiology and pharmacology. Pharmacol. Rev., 43, 109-142.
17. Neff, M.S., Kim, K.E., Persoff, M., Onesti, G. & Swartz, C. (1971). Hemodynamics of uremic anemia. Circulation, 43, 876-883.
18. Raine, A.E.G. (1988). Hypertension, blood viscosity and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet, 1, 97-98.
19. Recny, M.A., Scoble, H.A. & Kim, Y. (1987). Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin: identification of des-arginine 166 erythropoietin. J. Biol. Chem., 262, 17156-17163.
20. Rimar, S. & Gillis, C.N. (1993). Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation, 88, 288-2887.
21. Southan, R.S., Abels, R.I. & Krants, S.B. (1996). Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol., 51, 383-394.
22. Squadrito, F., Altavilla, D., Canale, P., Ioculano, M., Campo, G.M., Ammendolia, L., Ferlito, M., Zingarelli, B., Squadrito, G., Saitta, A. & Caputi, A.P. (1994a). Participation of tumor necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock. Br. J. Pharmacol., 113, 1153-1158.
23. Squadrito, F., Altavilla, D., Canale, P., Ioculano, M., Campo, G.M., Ammendolia, L., Squadrito, G., Saitta, A., Calapai, G. & Caputi, A.P. (1994b). Contribution of intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of splanchnic artery occlusion shock in the rat. Br. J. Pharmacol., 113, 912-916.
24. Squadrito, F., Altavilla, D., Squadrito, G., Campo, G.M., Ioculano, M., Canale, P., Rossi, F., Saitta, A. & Caputi, A.P. (1996). Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock. Br. J. Pharmacol., 119, 23-28.
25. Stein, R.S., Abels, R.I. & Krants, S.B. (1991). Pharmacological doses of recombinanthuman erythropoietin in the treatment of myelodysplastic syndromes. Blood, 75, 1658-1663.
26. Szabo', C., Southan, G.J., Wood, E., Thiemermann, C. & Vane, J.R. (1994). Spermine inhibits the production of nitric oxide in immune-stimulated J774.2 macrophages: requirement of a serum factor. Br. J. Pharmacol., 112, 335-356.
27. Szabo', C. & Thiemermann, C. (1994). Invited opinion: role of nitric oxide in hemorrhagic, traumatic and anaphylactic shock and thermal injury. Shock, 2, 145-155.
28. Thiemermann, C., Szabo', C., Mitchell, J.A. & Vane, J.R. (1993). Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc. Natl. Acad. Sci. U.S.A., 90, 267-271.
29. Wennmain, A., Benthin, G. & Petersson, A.S. (1992). Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br. J. Pharmacol., 106, 507-508.